A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Exclusion Criteria

• •Women who are pregnant or lactating
• •Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period
• •Known metastatic disease to the central nervous system
• •Presence of bulky disease (defined as any single mass \> 10 cm in its greatest dimension)
• •Patients with \> Grade 2 nausea or vomiting and/or signs of intestinal obstruction
• •Prior radiation dose \> 3,000 cGy to the liver, \> 2,000 cGy to lungs and kidneys or prior external beam irradiation to a field that includes more than 30% of the red marrow
• •Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not excluded, but patients with other prior malignancies must have had at least a 3-year disease free interval
• •Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive
• •Known history of active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months, or cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy
• •Known history of active COPD, or other moderate-to-severe respiratory illness present within 6 months
• •Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid arthritis requiring only low dose maintenance corticosteroids)
• •Infection requiring intravenous antibiotic use within 1 week
• •Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations